Early Life Interventions for Childhood Growth and Development In Tanzania
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,188
- 试验地点
- 1
- 主要终点
- Height-for-age z-score (HAZ) at 18 months
研究概览
简要总结
This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.
详细描述
Children living in rural sub-Saharan Africa experience massive challenges to child thriving, with poor linear growth and delays in child development. In a cohort of 211 children living in the rural Haydom area of Tanzania (participating in the Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development "MAL-ED" Study), 70.6% had stunted growth at 18 months. This rate of moderate and severe stunting (length-for-age z-score [HAZ] <-2 standard deviations) was the highest of the 8 study sites in MAL-ED.
This enormous deficit is likely associated with high rates of enteric infections with Campylobacter, E. coli pathotypes, Cryptosporidium, and Giardia, organisms susceptible to azithromycin and/or nitazoxanide. Infections such as these occur frequently in developing areas and are often associated with environmental enteropathy, including ongoing enteric inflammation and loss of enterocyte integrity, leading to possible bacterial translocation and poorer absorption of ingested nutrients. The consequences of these infections, enteric dysfunction and poor nutrient absorption frequently include growth stunting, learning delays, and an overall loss of human capital.
Emerging evidence suggests a potential role for the tryptophan-niacin pathway (including the end-product nicotinamide, an isoform of vitamin B3) in decreasing mucosal inflammation and affecting enteral microbiota. At the Tanzania site of MAL-ED, serum levels of tryptophan were related to subsequent linear growth, further suggesting importance of the tryptophan-niacin pathway. What is not clear is whether early childhood growth and development could be improved by targeting enteric infection and the tryptophan-niacin pathway by 1) delivering antibiotics against specific bacteria and/or 2) providing vitamin B3 as nicotinamide/niacinamide.
The main analysis will be intention-to-treat but a secondary analysis will be per protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Both participants and investigators will be blinded to the treatments allocated to each participant. The members of the DSMB will also be blinded.
入排标准
- 年龄范围
- 0 Days 至 14 Days(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Maternal age ≥18
- •Infant ≤ 14 days
排除标准
- •Maternal inability to adhere to protocol
- •Multiple gestation
- •Severe illness (significant birth defect, hospitalization, severe neonatal illness)
- •Birth weight <1500 g
- •Lack of breastfeeding at enrollment (and lack of intention to continue breastfeeding at time of enrollment).
研究组 & 干预措施
Nicotinamide and Antimicrobials
Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Azithromycin Oral Liquid Product (Drug)
Nicotinamide and Antimicrobials
Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Nitazoxanide Oral Suspension (Drug)
Nicotinamide and Antimicrobials
Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Nicotinamide (Dietary Supplement)
Antimicrobials only
Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Azithromycin Oral Liquid Product (Drug)
Antimicrobials only
Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Nitazoxanide Oral Suspension (Drug)
Antimicrobials only
Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
干预措施: Placebos (Drug)
Nicotinamide only
Nicotinamide Placebo Placebo
干预措施: Nicotinamide (Dietary Supplement)
Nicotinamide only
Nicotinamide Placebo Placebo
干预措施: Placebos (Drug)
No active treatment
Placebo Placebo Placebo
干预措施: Placebos (Drug)
结局指标
主要结局
Height-for-age z-score (HAZ) at 18 months
时间窗: 18 months
次要结局
- Stunting(18 months)
- All cause mortality(0-18 months)
- Weight-for-age z-score (WAZ) at 18 months(18 months)
- Head circumference-for-age z-score (HCAZ) at 18 months(18 months)
- Hospitalization(0-18 months)
- Childhood illness(0-18 months)
- Anemia(12 and 18 months)
- Enteropathogen burden(6, 6.5, 12, 12.5, 18 months)
- Microbiota composition(6, 6.5, 12, 18 months)
- Stool myeloperoxidase concentration(6, 12, 18 months)
- C-reactive protein concentration in serum(12 and 18 months)
- Insulin-like growth factor 1 concentration in serum(12 and 18 months)
- Collagen X concentration in serum(12 and 18 months)
- Tryptophan-kynurenine ratio(12 and 18 months)
- Niacin and nicotinamide metabolite concentration(6, 12, 18 months)
- Small intestinal bacterial overgrowth(6, 12 and 18 months)
- Malawi Developmental Assessment Tool score(18 months)
